MX2015005313A - Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil. - Google Patents

Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.

Info

Publication number
MX2015005313A
MX2015005313A MX2015005313A MX2015005313A MX2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A
Authority
MX
Mexico
Prior art keywords
elution
mops
biomolecules
mes
mobile phase
Prior art date
Application number
MX2015005313A
Other languages
English (en)
Inventor
Daniel Cummings
Veena Warikoo
Rahul Godawat
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015005313A publication Critical patent/MX2015005313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/16—Holders for containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a métodos para purificar o enriquecer una biomolécula utilizando resinas multimodales y un tampón de elución que contiene un tampón de Good.
MX2015005313A 2012-10-24 2013-10-23 Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil. MX2015005313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717880P 2012-10-24 2012-10-24
PCT/US2013/066319 WO2014066471A1 (en) 2012-10-24 2013-10-23 Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers

Publications (1)

Publication Number Publication Date
MX2015005313A true MX2015005313A (es) 2016-04-06

Family

ID=49554488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005313A MX2015005313A (es) 2012-10-24 2013-10-23 Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.

Country Status (10)

Country Link
US (2) US20150275195A1 (es)
EP (1) EP2911759B1 (es)
CN (3) CN105777862A (es)
AU (3) AU2013334644B2 (es)
CA (1) CA2888824C (es)
DK (1) DK2911759T3 (es)
HK (1) HK1222868A1 (es)
MX (1) MX2015005313A (es)
SG (2) SG10201901695RA (es)
WO (1) WO2014066471A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777862A (zh) * 2012-10-24 2016-07-20 建新公司 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
SG10201709131UA (en) 2013-03-08 2017-12-28 Genzyme Corp Continuous purification of therapeutic proteins
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
CA3084827A1 (en) * 2017-12-29 2019-07-04 Baxalta Incorporated Adeno-associated virus purification methods
CN108479110A (zh) * 2018-04-10 2018-09-04 深圳市菲鹏生物制药股份有限公司 一种细胞培养液脱色剂及脱色方法
CA3110666A1 (en) 2018-08-31 2020-03-05 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
DE102020214647A1 (de) 2020-11-20 2022-05-25 DIL Deutsches Institut für Lebensmitteltechnik e.V. Anthocyanhaltiges Extraktpulver und Verfahren zur Herstellung

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347322A (en) * 1981-01-12 1982-08-31 Nabisco Brands, Inc. Chromatographic process for enzyme purification
US4663288A (en) * 1985-05-22 1987-05-05 Nabisco Brands, Inc. Process for purification of enzymes
HU230275B1 (hu) 1996-09-13 2015-11-30 Shire Human Genetic Therapies, Inc Eljárás tisztított humán alfa-galaktozidáz-A készítmények előállítására, és a tisztított készítményeket tartalmazó gyógyászati készítmények, alfa-gal-A-deficienciából eredő rendellenességek kezelésében történő alkalmazásra
EP1866427A4 (en) * 2005-03-30 2010-09-01 Novo Nordisk As MANUFACTURING PROCESS FOR THE PRODUCTION OF CULTIVE PEPTIDES IN CELL LINES OF INSECTS
US20080090278A1 (en) * 2006-03-31 2008-04-17 Toyo Boseki Kabushiki Kaisha Method for enhancing stability of a composition comprising soluble glucose dehydrogenase (gdh)
PL2167526T3 (pl) 2007-07-11 2011-09-30 Novo Nordisk As Oczyszczanie czynnika VIII za pomocą żywicy o mieszanej funkcji lub wielofunkcyjnej
WO2009092014A1 (en) * 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5619738B2 (ja) 2008-06-24 2014-11-05 オクタファルマ アクチェンゲゼルシャフト 凝固第ｖｉｉｉ因子の精製方法
US20110166332A1 (en) 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
CA2697999C (en) * 2009-04-24 2013-04-30 Werner Hoelke A stabilized aqueous alpha-galactosidase composition and methods relating thereto
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
US8951807B2 (en) * 2010-01-15 2015-02-10 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
WO2011121020A1 (en) 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
RU2015149979A (ru) * 2010-03-30 2019-01-15 Октафарма Аг Способ очистки белка фактора роста
US9422329B2 (en) * 2010-11-05 2016-08-23 Hoffmann-La Roche Inc. Optimized method for antibody capturing by mixed mode chromatography
EP2638156B1 (de) * 2010-11-09 2016-01-27 Qiagen GmbH Verfahren und vorrichtung zur isolierung und reinigung von doppelsträngigen nukleinsäuren
CN103732610A (zh) * 2011-06-13 2014-04-16 默沙东公司 纯化天然或突变体形式的白喉毒素的方法
BR112014010406A2 (pt) 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
CN105777862A (zh) * 2012-10-24 2016-07-20 建新公司 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
EA032680B1 (ru) * 2012-11-13 2019-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. ОЧИСТКА РЕКОМБИНАНТНОЙ ГАЛАКТОЦЕРЕБРОЗИД-БЕТА-ГАЛАКТОЗИДАЗЫ ЧЕЛОВЕКА (rhGALC)
TWI631132B (zh) * 2013-05-06 2018-08-01 賽諾菲公司 用於純化抗體之連續多步驟方法

Also Published As

Publication number Publication date
DK2911759T3 (da) 2024-09-16
EP2911759A1 (en) 2015-09-02
AU2018241214A1 (en) 2018-11-01
CN105777862A (zh) 2016-07-20
SG10201901695RA (en) 2019-03-28
CA2888824C (en) 2021-02-02
AU2013334644A1 (en) 2015-05-07
AU2020203008A1 (en) 2020-05-28
AU2013334644B2 (en) 2018-07-12
WO2014066471A1 (en) 2014-05-01
HK1222868A1 (zh) 2017-07-14
EP2911759B1 (en) 2024-07-17
AU2018241214B2 (en) 2020-02-06
CN104884147A (zh) 2015-09-02
CN111172135A (zh) 2020-05-19
CA2888824A1 (en) 2014-05-01
SG11201502918RA (en) 2015-05-28
AU2020203008B2 (en) 2022-06-16
AU2018241214B9 (en) 2020-02-20
US20150275195A1 (en) 2015-10-01
US11203747B2 (en) 2021-12-21
US20200131493A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2015005313A (es) Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MY193249A (en) Anti-human cd19 antibodies with high affinity
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12014501108A1 (en) Anti-il-36r antibodies
MY174025A (en) Azole silane compound, surface treatment solution, surface treatment method, and use thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX358367B (es) Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos.
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2013149111A3 (en) Anti-tlr4 antibodies and uses thereof
EP2992021A4 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
PL3200822T3 (pl) Cząsteczki wiążące, zwłaszcza przeciwciała, które wiążą się z l1cam (cd171)
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MX336369B (es) Uso de acido elagico como agentes anticaspa.
SI2938609T1 (sl) Postopek za pripravo 1-((1,3)dioksolan-4-ilmetil)-1H-pirazol-3-ilamina
WO2013093627A3 (en) In silico affinity maturation
MX2015014935A (es) Metodo para sintetizar conjugados de anticuerpo-farmaco usando resinas de afinidad.
WO2013011062A3 (en) Antagonistic antibodies against oscar